Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells

The initial success of the first synthetic bcr-abl kinase inhibitor imatinib has been dampened by the emergence of imatinib-resistant disease in blast crisis chronic myeloid leukemia. Here, we report that the novel triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate (CDDO-Me) potently induced cytotoxicity in imatinib-resistant KBM5 cells expressing the T315I mutation of bcr-abl (24-h EC50, 540 nmol/L). In long-term culture, CDDO-Me abrogated the growth of human parental KBM5 and KBM5-STI cells with 96-h IC50 of 205 and 221 nmol/L, respectively. In addition, CDDO-Me rapidly decreased the viability of murine lymphoid Ba/F3 cells expressing wild-type p210 as well as the imatinib-resistant E255K and T315I mutations of bcr-abl. The low-dose effects of CDDO-Me are associated with inhibition of mitochondrial oxygen consumption, whereas the cytotoxic effects appear to be mediated by a rapid and selective depletion of mitochondrial glutathione that accompanies the increased generation of reactive oxygen species and mitochondrial dysfunction. Interestingly, the mitochondriotoxic effects of CDDO-Me are followed by the rapid autophagocytosis of intracellular organelles or the externalization of phosphatidylserine in different cell types. We conclude that alterations in mitochondrial function by CDDO-Me can result in autophagy or apoptosis of chronic myeloid leukemia cells regardless of the mutational status of bcr-abl. CDDO-Me is in clinical trials and shows signs of clinical activity, with minimal side effects and complete lack of cardiotoxicity. Studies in leukemias are in preparation. [Mol Cancer Ther 2008;7(5):1130–9]

[1]  Jorge Cortes,et al.  Flying under the radar: the new wave of BCR–ABL inhibitors , 2007, Nature Reviews Drug Discovery.

[2]  D. Bergstrom,et al.  MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. , 2007, Blood.

[3]  Jinsong Liu,et al.  Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. , 2006, Cancer cell.

[4]  K. Bhalla,et al.  Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. , 2006, The New England journal of medicine.

[5]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[6]  H. Kantarjian,et al.  New Strategies in Chronic Myeloid Leukemia , 2006, International journal of hematology.

[7]  Sudeshna Dutta,et al.  Autophagic programmed cell death by selective catalase degradation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Y. Kondo,et al.  Autophagy and Cancer Therapy , 2006, Autophagy.

[9]  M. Konopleva,et al.  A Novel Mechanism of Action of Methyl-2-cyano-3,12 Dioxoolean-1,9 Diene-28-oate: Direct Permeabilization of the Inner Mitochondrial Membrane to Inhibit Electron Transport and Induce Apoptosis , 2005, Molecular Pharmacology.

[10]  M. Sporn,et al.  2-Cyano-3,12-dioxooleana-1,9-dien-28-imidazolide (CDDO-Im) Directly Targets Mitochondrial Glutathione to Induce Apoptosis in Pancreatic Cancer* , 2005, Journal of Biological Chemistry.

[11]  P. Petit,et al.  Role of cardiolipin on tBid and tBid/Bax synergistic effects on yeast mitochondria , 2005, Cell Death and Differentiation.

[12]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[13]  Martin C. Müller,et al.  Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center , 2005, Cancer.

[14]  A. Jin,et al.  BCR/ABL activates Rap1 and B-Raf to stimulate the MEK/Erk signaling pathway in hematopoietic cells. , 2005, Biochemical and biophysical research communications.

[15]  M. Sporn,et al.  The Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid Induces Caspase-Dependent and -Independent Apoptosis in Acute Myelogenous Leukemia , 2004, Cancer Research.

[16]  T. Kurosu,et al.  The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ABL fusion kinase. , 2004, Biochemical and biophysical research communications.

[17]  Y. Nakagawa.  Role of mitochondrial phospholipid hydroperoxide glutathione peroxidase (PHGPx) as an antiapoptotic factor. , 2004, Biological & pharmaceutical bulletin.

[18]  A. Hochhaus,et al.  Clinical resistance to imatinib: mechanisms and implications. , 2004, Hematology/oncology clinics of North America.

[19]  B. Calabretta,et al.  The biology of CML blast crisis. , 2004, Blood.

[20]  G. Cohen,et al.  CDDO induces apoptosis via the intrinsic pathway in lymphoid cells , 2004, Leukemia.

[21]  O. Wagner,et al.  Identification of heme oxygenase-1 as a novel BCR/ABL-dependent survival factor in chronic myeloid leukemia. , 2004, Cancer research.

[22]  Y. Nakagawa.  Initiation of Apoptotic Signal by the Peroxidation of Cardiolipin of Mitochondria , 2004, Annals of the New York Academy of Sciences.

[23]  M. Sporn,et al.  Evidence Supporting a Role for Calcium in Apoptosis Induction by the Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid (CDDO)* , 2004, Journal of Biological Chemistry.

[24]  F. E. Bertrand,et al.  JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis , 2004, Leukemia.

[25]  M. Sporn,et al.  Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid. , 2004, Molecular cancer therapeutics.

[26]  H. Kantarjian,et al.  Survival Advantage with Imatinib Mesylate Therapy in Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) after IFN-α Failure and in Late CML-CP, Comparison with Historical Controls , 2004, Clinical Cancer Research.

[27]  M. Sporn,et al.  The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance. , 2003, Cancer research.

[28]  J. Fernandez-Checa,et al.  Redox regulation and signaling lipids in mitochondrial apoptosis. , 2003, Biochemical and biophysical research communications.

[29]  M. Lupi,et al.  Mitochondrial dysfunction and death in motor neurons exposed to the glutathione-depleting agent ethacrynic acid , 2003, Journal of the Neurological Sciences.

[30]  H. Kantarjian,et al.  Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. , 2002, Cancer research.

[31]  Gabriela Chiosis,et al.  BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. , 2002, Blood.

[32]  C. Barthe,et al.  Mutation in the ATP‐binding site of BCR‐ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571 , 2002, British journal of haematology.

[33]  G. Pérez-Yarza,et al.  Implication of mitochondria-derived ROS and cardiolipin peroxidation in N-(4-hydroxyphenyl)retinamide-induced apoptosis , 2002, British Journal of Cancer.

[34]  Tadashi Honda,et al.  Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. , 2002, Blood.

[35]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[36]  B. Druker,et al.  STI571: targeting BCR-ABL as therapy for CML. , 2001, The oncologist.

[37]  M. Sporn,et al.  The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism. , 2001, Molecular pharmacology.

[38]  H. Imai,et al.  Mitochondrial phospholipid hydroperoxide glutathione peroxidase inhibits the release of cytochrome c from mitochondria by suppressing the peroxidation of cardiolipin in hypoglycaemia-induced apoptosis. , 2000, The Biochemical journal.

[39]  W. Dröge,et al.  Glutathione is a factor of resistance of Jurkat leukemia cells to nitric oxide‐mediated apoptosis , 2000, Journal of cellular biochemistry.

[40]  N. Danial,et al.  JAK-STAT signaling activated by Abl oncogenes , 2000, Oncogene.

[41]  M. Sporn,et al.  The novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[42]  F. Corrales,et al.  Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. , 1998, Gastroenterology.

[43]  L. Varticovski,et al.  Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase , 1997, Oncogene.

[44]  R. Kurzrock,et al.  Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. , 1993, Cancer research.